Active spinal muscular atrophy clinical trials by region and phase 2023
The United States represented the highest number of active clinical trials for spinal muscular atrophy (SMA), as of 2023, totaling 26 trials. Spinal muscular atrophy (SMA) is a genetic/inherited neuromuscular disorder that leads to weakness and atrophy in skeletal muscles. This statistic depicts the number of active clinical trials of spinal muscular atrophy (SMA) treatments, as of July 2023, by region and trial phase.